AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

1. (Cancelled).

2. (Currently amended) Crystalline oxcarbazepine, wherein the oxcarbazepine has ~~having~~ a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta.

3. (Original) The oxcarbazepine of claim **2** having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 17.7, 19.4, 20.0, 21.1, 23.0, 24.0, 24.4 ,25.1, 26.0 ± 0.2 degrees two-theta.

4. (Original) The oxcarbazepine of claim **3** having a PXRD diffraction pattern substantially as depicted in figure 1.

5. (Currently amended) A process for preparing the oxcarbazepine of claim **2** ~~Form B~~ comprising the steps of:
   a) preparing a solution of oxcarbazepine in a mixture of dichloromethane and toluene, and
   b) evaporating the toluene and the dichloromethane leaving the oxcarbazepine ~~Form B~~ as a residue.

6. (Original) The process of claim **5**, wherein the solution is prepared by dissolving oxcarbazepine in dichloromethane and adding the dichloromethane to toluene.

7. (Currently amended) ~~The~~ Crystalline oxcarbazepine ~~Form B~~ having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta prepared by the process of claim **5**.

8. (Currently amended) A process for preparing the oxcarbazepine of claim 2 ~~Form B~~ comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene;

b) heating the solution;

c) cooling the solution at a rate of 60°C min^{-1} or above to cause formation of a precipitate; and

d) separating the precipitate.

9. (Original) The process of claim **8**, wherein the solution is heated to about reflux.

10. (Original) The process of claim **8**, wherein the solution is cooled to a temperature of about 0°C.

11. (Currently amended) ~~The~~ Crystalline oxcarbazepine ~~Form B~~ having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta prepared by the process of claim **8**.

12. (Cancelled).

13. (Currently amended) Crystalline oxcarbazepine, wherein the oxcarbazepine has a ~~characterized by~~ PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta.

14. (Currently amended) The oxcarbazepine of claim **13** having a ~~characterized by~~ PXRD diffraction pattern with peaks at about 11.7, 17.0, 18.0, 21.7, 23.2, 24.4, 26.0 ± 0.2 degrees two-theta.

15. (Currently amended) The oxcarbazepine of claim **14** having ~~characterized by~~ a PXRD diffraction pattern substantially as depicted in figure 2.

16. (Currently amended) A process for preparing the oxcarbazepine of claim **13** ~~Form C~~ comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene;

b) heating the solution;

c) cooling the solution at a rate of from about 20 to 60°C min.$^{-1}$ to cause formation of a precipitate; and

d) separating the precipitate.

17. (Original) The process of claim **16**, wherein the solution is cooled at a rate of about 40°C per minute.

18. (Original) The process of claim **16**, wherein the solution is cooled to about 0°C.

19. (Original) The process of claim **16**, wherein the solution is heated to about reflux.

20. (Currently amended) ~~The~~ Crystalline oxcarbazepine ~~Form C~~ having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta prepared by the process of claim **16**.

21. (Cancelled).

22. (Currently amended) Crystalline oxcarbazepine, wherein the oxcarbazepine has a ~~characterized by~~ PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta.

23. (Currently amended) The oxcarbazepine of claim **22** ~~characterized by~~ having a PXRD diffraction pattern substantially as depicted in figure 3.

24. (Currently amended) A process for preparing the oxcarbazepine of claim **22** ~~Form D~~ comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene; and

b) evaporating the toluene leaving a residue of the oxcarbazepine ~~Form D~~.

25. (Original) The process of claim **24**, further comprising a step of heating the solution before evaporating.

26. (Original) The process of claim **25**, wherein the solution is heated to about reflux.

27. (Original) The process of claim **25**, further comprising cooling the heated solution before evaporating.

28. (Original) The process of claim **27**, wherein the solution is cooled to about 0°C.

29. (Original) The process of claim **24**, further comprising a step of cooling the solution.

30. (Original) The process of claim **29**, wherein the solution is cooled to about 0°C.

31. (Original) The process of claim **24**, wherein the toluene is removed from the solution by evaporation.

32. (Currently amended) ~~The~~ Crystalline oxcarbazepine ~~Form D~~ having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta prepared by the process of claim **24**.

33. (Original) An oxcarbazepine chloroform solvate.

34. (Cancelled).

35. (Currently amended) ~~An~~ crystalline oxcarbazepine chloroform solvate, wherein the oxcarbazepine has ~~characterized by~~ a PXRD diffraction pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta.

36. (Currently amended) The oxcarbazepine chloroform solvate of claim **35**, wherein the oxcarbazepine has ~~characterized by~~ a PXRD diffraction pattern substantially as depicted in figure 4.

37. (Original) The oxcarbazepine chloroform solvate of claim **33** containing about a 27 weight % chloroform.

38. (Original) A process for preparing oxcarbazepine chloroform solvate comprising:

a) causing formation of a precipitate from a solution of oxcarbazepine in chloroform, and

b) separating the precipitate.

39. (Original) The process of claim **38**, further comprising a step of heating the solution before causing formation of the precipitate.

40. (Original) The process of claim **39**, further comprising a step of cooling the heated solution, whereby cooling causes formation of the precipitate.

41. (Original) The process of claim **39**, wherein the solution is heated to an elevated temperature of from about 50°C to about 60°C.

42. (Original) The process of claim **41**, wherein the solution is heated to an elevated temperature of about 55°C.

43. (Original) The process of claim **41**, wherein the heated solution is cooled to a reduced temperature of from about 10°C to about 20°C.

44. (Original) The process of claim **43**, wherein the reduced temperature is about 16°C.

45. (Original) The oxcarbazepine chloroform solvate produced by the process of claim **37**.

46. (Currently amended) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 ~~Form A~~ comprising:

a) providing the oxcarbazepine chloroform solvate of claim **35** ~~Form E~~,

b) heating the oxcarbazepine chloroform solvate, and

c) recovering the oxcarbazepine ~~as Form A~~.

47. (Currently amended) The process of claim **46**, wherein the oxcarbazepine solvate ~~Form E~~ is heated to an elevated temperature in the range of from about 40°C to about 80°C.

48. (Original) The process of claim **47**, wherein the elevated temperature is about 60°C.

49. (Currently amended) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 ~~Form A~~ comprising

a) providing crystalline oxcarbazepine ~~Form B~~ having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta,

b) heating the oxcarbazepine, and

c) recovering the oxcarbazepine ~~as Form A~~.

50. (Currently amended) The process of claim **49**, wherein the oxcarbazepine ~~Form B~~ is heated to an elevated temperature in the range of from about 60°C to about 120°C.

51. (Original) The process of claim **50**, wherein the elevated temperature is about 60°C.

52. (Currently amended) A process for the preparation of crystalline oxcarbazepine ~~Form C~~ having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta comprising

a) providing crystalline oxcarbazepine ~~Form B~~ having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta,

b) maintaining the oxcarbazepine at a temperature in the range of from about 20 to about 30°C, and

c) recovering the oxcarbazepine ~~as Form C~~.

53. (Currently amended) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 ~~Form A~~ comprising:

a) contacting oxcarbazepine selected from the group consisting of ~~oxcarbazepine Form B, oxcarbazepine Form C and oxcarbazepine Form D~~ crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta, and crystalline oxcarbazepine having a PXRD

diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta with a protic solvent; and

b) recovering the oxcarbazepine ~~as Form A~~.

54. (Currently amended) The process of claim **53**, wherein the ~~forms of~~ crystalline oxcarbazepine ~~are~~ is suspended in the protic solvent.

55. (Original) The process of claim **53**, wherein the protic solvent is selected from the group consisting of water and ethanol.

56. (Currently amended) The process of claim **54**, wherein the crystalline oxcarbazepine is suspended in the protic solvent from about two hours to about three days.

57. (Currently amended) The process of claim **56**, wherein the crystalline oxcarbazepine is suspended for about one day.

58. (Currently amended) A pharmaceutical composition comprising:

a) oxcarbazepine selected from the group consisting of ~~oxcarbazepine Form B, oxcarbazepine Form C, oxcarbazepine Form D and oxcarbazepine Form E~~ crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta, and crystalline oxcarbazepine chloroform solvate having a PXRD diffraction pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta; and

b) a pharmaceutically acceptable excipient.

59. (Currently amended) The pharmaceutical composition of claim **58**, wherein the composition is mixed with one or more ~~forms of~~ crystalline oxcarbazepine.

60. (Original) A pharmaceutical dosage form comprising the pharmaceutical composition of claim **58**.

61. (Original) The pharmaceutical dosage form of claim **60**, wherein the dosage form is a capsule or tablet.

62. (Original) The pharmaceutical dosage form of claim **61**, wherein the dosage form is a tablet.

63. (Original) The pharmaceutical dosage form of claim **60**, containing a unit dosage of about 150mg to about 600mg oxcarbazepine.

64. (Original) The pharmaceutical dosage form of claim **63**, containing a unit dosage selected from the group consisting of about 150mg, 300mg and 600mg.

65. (Original) The pharmaceutical dosage form of claim **60**, wherein the dosage form is an oral suspension.

66. (Original) The pharmaceutical dosage form of claim **65**, wherein the dosage is about 60mg ml^{-1}.

67. (Original) The pharmaceutical dosage form of claim **66**, wherein the dosage is about 300mg ml^{-1}.

68. (Original) A method of preventing or reducing the severity of seizures comprising administrating the pharmaceutical composition of claim **58**.

69. (Original) The method of claim **68**, wherein the seizures are associated with epilepsy.

70. (Original) A method of treating Parkinson's disease comprising administrating the pharmaceutical composition of claim **58**.

71. (Original) A method of depressing the central nervous system comprising administering the pharmaceutical composition of claim **58**.

72. (Original) The method of claim **71**, wherein the central nervous system is depressed by blocking voltage sensitive sodium channels.